Log in

Relevant bibliographies by topics / Proprotein convertase subtilisin/kexin type 9 / Journal articles

To see the other types of publications on this topic, follow the link: Proprotein convertase subtilisin/kexin type 9.

Journal articles on the topic 'Proprotein convertase subtilisin/kexin type 9'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Proprotein convertase subtilisin/kexin type 9.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Macchi, Chiara, Nicola Ferri, Chiara Favero, et al. "Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals." European Journal of Preventive Cardiology 26, no. 6 (2018): 578–88. http://dx.doi.org/10.1177/2047487318815320.

Full text

Abstract:

Aims Exposure to airborne particulate matter has been consistently associated with early death and increased morbidity, particularly raising the risk of cardiovascular disease. Obesity, one of the leading cardiovascular disease risk factors, increases susceptibility to the adverse effects of particulate matter exposure. Proprotein convertase subtilisin/kexin type 9 has been related to a large number of cardiovascular risk factors, e.g. atherogenic lipoproteins, arterial stiffness and platelet activation. Thus, the present study was aimed at evaluating, in a series of obese individuals, the eff

APA, Harvard, Vancouver, ISO, and other styles

2

Stoekenbroek, Robert M., and John J. P. Kastelein. "Proprotein convertase subtilisin/kexin type 9." Current Opinion in Cardiology 33, no. 3 (2018): 269–75. http://dx.doi.org/10.1097/hco.0000000000000517.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Sahebkar, Amirhossein. "Proprotein Convertase Subtilisin/Kexin Type 9." Angiology 65, no. 3 (2013): 243. http://dx.doi.org/10.1177/0003319713512016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sinan, Umit Yasar. "Proprotein Convertase Subtilisin/Kexin Type 9." Angiology 65, no. 3 (2013): 244. http://dx.doi.org/10.1177/0003319713512558.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bergeron, Nathalie, Binh An P. Phan, Yunchen Ding, Aleyna Fong, and Ronald M. Krauss. "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition." Circulation 132, no. 17 (2015): 1648–66. http://dx.doi.org/10.1161/circulationaha.115.016080.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Farnier, Michel. "Proprotein convertase subtilisin kexin type 9 inhibitors." Current Opinion in Lipidology 27, no. 6 (2016): 597–604. http://dx.doi.org/10.1097/mol.0000000000000356.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Marais, David A., Dirk J. Blom, Francine Petrides, Yann Gouëffic, and Gilles Lambert. "Proprotein convertase subtilisin/kexin type 9 inhibition." Current Opinion in Lipidology 23, no. 6 (2012): 511–17. http://dx.doi.org/10.1097/mol.0b013e3283587563.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Zenti, Maria G., Anna Altomari, Maria G. Lupo, et al. "From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients." European Journal of Preventive Cardiology 25, no. 17 (2018): 1843–51. http://dx.doi.org/10.1177/2047487318792626.

Full text

Abstract:

In this observational study, we compared the effect of lipoprotein apheresis and evolocumab or alirocumab on levels of lipoprotein cholesterol, triglycerides and inflammatory markers (C reactive protein and interleukin 6) in cardiovascular patients ( n = 9). Patients were monitored during the last year of lipoprotein apheresis followed by six months of treatment with proprotein convertase subtilisin/kexin type 9 inhibitors. The biochemical parameters were determined pre- and post- every apheresis procedure for 12 months and then after one, three and six months of treatment with evolocumab (140

APA, Harvard, Vancouver, ISO, and other styles

9

Hess, Gregory P., Pradeep Natarajan, Kamil F. Faridi, Anna Fievitz, Linda Valsdottir, and Robert W. Yeh. "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy." Circulation 136, no. 23 (2017): 2210–19. http://dx.doi.org/10.1161/circulationaha.117.028430.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Leong, Derek, and Peter E. Wu. "Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors." Canadian Medical Association Journal 191, no. 32 (2019): E894. http://dx.doi.org/10.1503/cmaj.190107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Hoang, Van Bac, Vadim V. Tyrenko, Oksana V. Shcherbatyuk, Sergey G. Bologov, and Nikolay Yu Demyanenko. "The effect of proprotein convertase subtilisin kexin type 9 inhibitors on the survival of patients at extreme cardiovascular risk in real clinical practice." HERALD of North-Western State Medical University named after I.I. Mechnikov 16, no. 4 (2024): 35–44. https://doi.org/10.17816/mechnikov634428.

Full text

Abstract:

BACKGROUND: Among non-communicable diseases, cardiovascular diseases occupy a leading position in terms of mortality rate in developed countries, including Russia. In the clinical practice of the Russian Federation, almost all modern methods and means of treating patients with cardiovascular diseases are used. In particular, innovative lipid-lowering drugs are used, such as proprotein convertase inhibitors subtilisin/kexin type 9 — alirocumab and evolocumab. However, at the moment there is no complete information on how these drugs affect the survival of patients at extreme cardiovascular risk

APA, Harvard, Vancouver, ISO, and other styles

12

Hanton, Sally L., and Charles Van Heyningen. "Proprotein convertase subtilisin/kexin type 9 related familial hypercholesterolaemia." British Journal of Diabetes & Vascular Disease 12, no. 5 (2012): 256–59. http://dx.doi.org/10.1177/1474651412463256.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Schmit, David, Danilo Fliser, and Thimoteus Speer. "Proprotein convertase subtilisin/kexin type 9 in kidney disease." Nephrology Dialysis Transplantation 34, no. 8 (2019): 1266–71. http://dx.doi.org/10.1093/ndt/gfz122.

Full text

Abstract:

Abstract Chronic kidney disease (CKD) is associated with a substantially increased risk for the development of atherosclerotic cardiovascular (CV) disease. Accordingly, CV mortality is increased even in the earliest stages of CKD. In the general population and in CKD patients, high plasma levels of low-density lipoprotein cholesterol (LDL-C) are crucially involved in the initiation and progression of atherosclerotic vascular lesions. Lowering LDL-C by use of statins and/or ezetimibe represents the gold standard of lipid-lowering therapy, with a great body of evidence from several large clinica

APA, Harvard, Vancouver, ISO, and other styles

14

Macchi, Chiara, Maria Francesca Greco, Margherita Botta, et al. "Leptin, Resistin, and Proprotein Convertase Subtilisin/Kexin Type 9." American Journal of Pathology 190, no. 11 (2020): 2226–36. http://dx.doi.org/10.1016/j.ajpath.2020.07.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Spolitu, Stefano, Wen Dai, John A. Zadroga, and Lale Ozcan. "Proprotein convertase subtilisin/kexin type 9 and lipid metabolism." Current Opinion in Lipidology 30, no. 3 (2019): 186–91. http://dx.doi.org/10.1097/mol.0000000000000601.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Pavlicek, Valérie, Daniel Urban, and Ulrich Laufs. "Hemmung der Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)." CardioVasc 13, no. 6 (2013): 44–48. http://dx.doi.org/10.1007/s15027-013-0271-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Simonen, Piia, Ulf-Håkan Stenman, and Helena Gylling. "Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study." Clinical Science 129, no. 5 (2015): 439–46. http://dx.doi.org/10.1042/cs20150193.

Full text

Abstract:

The present randomized, controlled clinical intervention demonstrated that plant stanol ester consumption does not affect serum proprotein convertase subtilisin/kexin type 9 concentration thus offering an effective dietary means to lower LDL cholesterol concentration.

APA, Harvard, Vancouver, ISO, and other styles

18

LI, ChangYong, Yuan BAI, and YongWen QIN. "Research advances in proprotein convertase subtilisin/kexin type 9 inhibitors." Pharmaceutical Care and Research 13, no. 4 (2013): 241–44. http://dx.doi.org/10.5428/pcar20130401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Ali, Ali, Pierluigi Costanzo, and Angela Hoye. "Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention." Current Pharmaceutical Design 24, no. 4 (2018): 442–50. http://dx.doi.org/10.2174/1381612824666180111105201.

Full text

Abstract:

Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events. However, despite high dose statin therapy, LDL-C control may remain inadequate in some patients, particularly those with familial hypercholesterolemia. A new therapeutic approach has emerged in recent years with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In this review, we des

APA, Harvard, Vancouver, ISO, and other styles

20

Blumenthal, Roger S., Khurram Nasir, and Seth S. Martin. "Realizing Value With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors." Circulation 138, no. 8 (2018): 767–69. http://dx.doi.org/10.1161/circulationaha.118.035156.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Koutagiar, I., C. Vlachopoulos, D. Terentes-Printzios, et al. "Proprotein convertase subtilisin/ kexin type 9 levels and arterial function." Atherosclerosis 275 (August 2018): e132. http://dx.doi.org/10.1016/j.atherosclerosis.2018.06.385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Filippatos, Theodosios D., Eliza C. Christopoulou, and Moses S. Elisaf. "Pleiotropic effects of proprotein convertase subtilisin/kexin type 9 inhibitors?" Current Opinion in Lipidology 29, no. 4 (2018): 333–39. http://dx.doi.org/10.1097/mol.0000000000000523.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Chan, Dick C. "Regulation of proprotein convertase subtilisin/kexin type 9: Therapeutical perspectives." Atherosclerosis 217, no. 1 (2011): 77–79. http://dx.doi.org/10.1016/j.atherosclerosis.2011.02.040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Julius, U., S. Tselmin, U. Schatz, S. Fischer, and S. R. Bornstein. "Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors." Clinical Research in Cardiology Supplements 14, S1 (2019): 45–50. http://dx.doi.org/10.1007/s11789-019-00099-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Noel, Zachary R., and Craig J. Beavers. "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview." American Journal of Medicine 130, no. 2 (2017): 229.e1–229.e4. http://dx.doi.org/10.1016/j.amjmed.2016.09.021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Dua, Pamila, and KH Reeta. "PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review." Journal of the Practice of Cardiovascular Sciences 6, no. 3 (2020): 226. http://dx.doi.org/10.4103/jpcs.jpcs_3_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Huang, Ya-Ping, Yun-Shan Wang, Bi-Wen Liu, et al. "Dammarane-type saponins with proprotein convertase subtilisin/kexin type 9 inhibitory activity from Gynostemma pentaphyllum." Phytochemistry 194 (February 28, 2022): 1–11. https://doi.org/10.1016/j.phytochem.2021.113005.

Full text

Abstract:

Huang, Ya-Ping, Wang, Yun-Shan, Liu, Bi-Wen, Song, Zhe, Liang, Xiao-Shuang, Teng, Yuan, Zhang, Jian, Yin, Zhi-Qi, Pan, Ke (2022): Dammarane-type saponins with proprotein convertase subtilisin/kexin type 9 inhibitory activity from Gynostemma pentaphyllum. Phytochemistry (113005) 194: 1-11, DOI: 10.1016/j.phytochem.2021.113005, URL: http://dx.doi.org/10.1016/j.phytochem.2021.113005

APA, Harvard, Vancouver, ISO, and other styles

28

Filippatos, Theodosios D., Anastazia Kei, Christos V. Rizos, and Moses S. Elisaf. "Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables." Journal of Cardiovascular Pharmacology and Therapeutics 23, no. 1 (2017): 3–12. http://dx.doi.org/10.1177/1074248417724868.

Full text

Abstract:

Low-density lipoprotein cholesterol (LDL-C) is a major cardiovascular risk factor, but other lipid variables such as triglycerides (TRGs), high-density lipoprotein cholesterol (HDL-C) and lipoprotein a [Lp(a)] also affect cardiovascular risk. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors significantly lower LDL-C concentration but also modestly improve the concentrations of TRGs and HDL-C and more robustly decrease Lp(a) levels. The review presents the associated mechanisms of the beneficial effects of PCSK9 inhibitors on the other than LDL-C lipid variables, including the e

APA, Harvard, Vancouver, ISO, and other styles

29

Stein, Evan A. "Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors in Clinical Practice: A Focused Update." US Cardiology Review 11, no. 2 (2017): 105. http://dx.doi.org/10.15420/usc.2017:23:1.

Full text

Abstract:

This article provides an updated review of the LDL-cholesterol efficacy, safety, and cardiovascular benefits of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. It focuses on evidence from numerous clinical trials and provides clinicians with a basis for understanding, assessing, and selecting these agents for clinical practice. It also provides some perspective on other potential agents in development that target PCSK9.

APA, Harvard, Vancouver, ISO, and other styles

30

Shapiro, Michael D., Joshua Miles, Hagai Tavori, and Sergio Fazio. "Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor." Annals of Internal Medicine 168, no. 5 (2017): 376. http://dx.doi.org/10.7326/m17-2485.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Shahreyar, Muhammed, Salem A. Salem, Mannu Nayyar, Lekha K. George, Nadish Garg, and Santhosh K. G. Koshy. "Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors." Journal of the American Board of Family Medicine 31, no. 4 (2018): 628–34. http://dx.doi.org/10.3122/jabfm.2018.04.170447.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Farnier, Michel. "The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia." American Journal Cardiovascular Drugs 11, no. 3 (2011): 145–52. http://dx.doi.org/10.2165/11590330-000000000-00000.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Kotani, Kazuhiko, and Maciej Banach. "Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9." Journal of Thoracic Disease 9, no. 1 (2017): E78—E82. http://dx.doi.org/10.21037/jtd.2017.01.40.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Sklar, Michael C., Claudia C. dos Santos, and Patrick R. Lawler. "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Survival in Sepsis." Critical Care Medicine 47, no. 3 (2019): 489–91. http://dx.doi.org/10.1097/ccm.0000000000003609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Bittner, Vera. "Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?" Circulation 134, no. 22 (2016): 1695–96. http://dx.doi.org/10.1161/circulationaha.116.023687.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Pihtili Taş, Nevsun, Rabia Aydogan Baykara, Ayhan Kamanli, et al. "Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome." Archives of Rheumatology 39, no. 3 (2024): 375–83. http://dx.doi.org/10.46497/archrheumatol.2024.10462.

Full text

Abstract:

Objectives: This study aimed to investigate the potential roles of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and apelin in the etiology of fibromyalgia syndrome (FS). Patients and methods: The retrospective study was conducted between May 2022 and February 2023. Fifty-eight female FS patients (mean age: 45.2±9.9 years; range, 25 to 66 years) and 30 age- and body mass index-matched control subjects (mean age: 43.1±9.9 years; range, 26 to 67 years) were included in the study. Apelin and PCSK9 levels of all individuals were measured using appropriate methods. Results: The levels of P

APA, Harvard, Vancouver, ISO, and other styles

37

Schmidt, Robert J., Youyan Zhang, Yang Zhao, et al. "A Novel Splicing Variant of Proprotein Convertase Subtilisin/Kexin Type 9." DNA and Cell Biology 27, no. 4 (2008): 183–89. http://dx.doi.org/10.1089/dna.2007.0667.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Koutagiar, Losif, Charalambos Vlachopoulos, Dimitrios Terentes-Printzios, et al. "P8 PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 LEVELS AND ARTERIAL FUNCTION." Artery Research 20, no. C (2017): 63. http://dx.doi.org/10.1016/j.artres.2017.10.061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Wang, Ya, Murong Ma, Jian-An Wang, Alan Daugherty, and Hong S. Lu. "Targeting proprotein convertase subtilisin/kexin type 9 in mice and monkeys." Current Opinion in Lipidology 30, no. 2 (2019): 154–55. http://dx.doi.org/10.1097/mol.0000000000000583.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Rakipovski, Günaj, G. Kees Hovingh, and Michael Nyberg. "Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?" Current Opinion in Lipidology 31, no. 6 (2020): 340–46. http://dx.doi.org/10.1097/mol.0000000000000718.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Alberts, Mark J., and Paul D. Thompson. "PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention." Stroke 51, no. 5 (2020): 1361–62. http://dx.doi.org/10.1161/strokeaha.120.028567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Vekić, Jelena, Dragana Bojanin, and Vesna Spasojević-Kalimanovska. "The role of proprotein convertase subtilisin/kexin type 9 in atherosclerosis." Biologia Serbica 41, no. 2 (2019): 9–14. https://doi.org/10.5281/zenodo.3532045.

Full text

Abstract:

<strong>Summary. </strong>Dyslipidemia is one of the predominant causes of atherosclerosis and cardiovascular disease (CVD) development. Accordingly, lifestyles approaches and therapeutic targeting of low-density lipoprotein (LDL)-cholesterol remain the main strategies for CVD prevention and treatment. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serin-protease with important roles in lipoprotein metabolism. In particular, PCSK9 promotes degradation of hepatic LDL-receptors, leading to reduced clearance of LDL particles and increased plasma LDL-cholesterol levels. To da

APA, Harvard, Vancouver, ISO, and other styles

43

Safaeian, Leila, Golnaz Vaseghi, Hedieh Jabari, and Nasim Dana. "Evolocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, promotes angiogenesis in vitro." Canadian Journal of Physiology and Pharmacology 97, no. 5 (2019): 352–58. http://dx.doi.org/10.1139/cjpp-2018-0542.

Full text

Abstract:

The proprotein convertases family is involved in several physiological processes such as cell growth, migration, and angiogenesis, and also in different pathological conditions. Evolocumab, an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), has recently been approved for treatment of hypercholesterolemia. This study aimed to investigate the effect of evolocumab on angiogenesis in human umbilical vein endothelial cells (HUVECs). Cell proliferation and migration were evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and Transwell methods. In vitro a

APA, Harvard, Vancouver, ISO, and other styles

44

Chaulin, A., L. Karslyan, A. Aleksandrov, A. Mazaev, E. Grigorieva, and D. Nurbaltaeva. "The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Atherosclerosis Development." Bulletin of Science and Practice 5, no. 5 (2019): 112–20. http://dx.doi.org/10.33619/2414-2948/42/15.

Full text

Abstract:

Elevated plasma low-density lipoprotein cholesterol (LDL-C) is an important risk factor for cardiovascular diseases. Statins are the most widely used therapy for patients with hyperlipidemia. However, a significant residual cardiovascular risk remains in some patients even after maximally tolerated statin therapy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new promising therapeutic target for decreasing LDL-C. PCSK9 reduces LDL intake from circulation by enhancing low-density lipoprotein receptors (LDLR) degradation and preventing LDLR recirculation to the cell surface. In addi

APA, Harvard, Vancouver, ISO, and other styles

45

Sun, Xiaowei, Rachid Essalmani, Robert Day, Abdel M. Khatib, Nabil G. Seidah, and Annik Prat. "Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver." Neoplasia 14, no. 12 (2012): 1122—IN5. http://dx.doi.org/10.1593/neo.121252.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

de Dios García-Díaz, Juan, Iraida M. Corral-Bueno, José María Mesa-Latorre, Cristina Lozano-Durán, and Concepción Hernández-Ahijado. "Proprotein Convertase Subtilisin/Kexin Type 9 Antibody and Statin-Associated Autoimmune Myopathy." Annals of Internal Medicine 171, no. 1 (2019): 68. http://dx.doi.org/10.7326/l18-0705.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Navarese, Eliano P., Michalina Kolodziejczak, Dean J. Kereiakes, Udaya S. Tantry, Christopher O'Connor, and Paul A. Gurbel. "Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome." Annals of Internal Medicine 164, no. 9 (2016): 600. http://dx.doi.org/10.7326/m15-2994.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Shafiq, Muhammad, Timothy Walmann, Venkat Nutalapati, Cheryl Gibson, and Yousaf Zafar. "Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver." World Journal of Hepatology 12, no. 12 (2020): 1258–167. http://dx.doi.org/10.4254/wjh.v12.i12.1258.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Turgeon, Ricky D., and Glen J. Pearson. "Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events." American Journal of Health-System Pharmacy 75, no. 11 (2018): 747–54. http://dx.doi.org/10.2146/ajhp170707.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Mangata, S. Ramin, and G. Lambert. "Proprotein convertase subtilisin kexin type 9 in human pancreatic beta cells physiology." Atherosclerosis 331 (August 2021): e44. http://dx.doi.org/10.1016/j.atherosclerosis.2021.06.126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!